{"doi":"10.1056/nejmoa2512071","title":"Sacituzumab Tirumotecan in EGFR-TKI–Resistant, <i>EGFR</i> -Mutated Advanced NSCLC","abstract":"BACKGROUND: -mutated non-small-cell lung cancer (NSCLC) that has progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy. METHODS: -mutated locally advanced or metastatic nonsquamous NSCLC that had progressed after EGFR-TKI therapy. The patients were randomly assigned, in a 1:1 ratio, to receive sac-TMT monotherapy or pemetrexed plus platinum-based chemotherapy. The primary end point was progression-free survival as assessed by blinded independent review. Overall survival was a hierarchically tested key secondary end point. In the interim analysis of progression-free survival as assessed by blinded independent review, sac-TMT monotherapy met the prespecified criterion for significance (two-sided P<0.0001); we report here the prespecified final analysis of progression-free survival and the preplanned interim analysis of overall survival. RESULTS: Overall, 376 patients underwent randomization, with 188 assigned to each group. After a median follow-up of 18.9 months, the median progression-free survival was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio for disease progression or death, 0.49; 95% confidence interval [CI], 0.39 to 0.62). Overall survival was significantly longer with sac-TMT than with chemotherapy (hazard ratio for death, 0.60; 95% CI, 0.44 to 0.82; two-sided P = 0.001); 18-month overall survival was 65.8% and 48.0%, respectively. Treatment-related adverse events of grade 3 or higher occurred in 58.0% of patients receiving sac-TMT and in 53.8% of those receiving chemotherapy, with the most common being a decreased neutrophil count (39.9% vs. 33.0%); treatment-related serious adverse events occurred in 9.0% and 17.6%, respectively. CONCLUSIONS: -mutated advanced or metastatic NSCLC that had progressed after previous EGFR-TKI therapy, progression-free survival and overall survival outcomes were significantly better with sac-TMT than with platinum-based chemotherapy. (Funded by Sichuan Kelun-Biotech Biopharmaceutical; OptiTROP-Lung04 ClinicalTrials.gov number, NCT05870319.).","journal":"New England Journal of Medicine","year":2025,"id":509165,"datarank":0.8838474717589242,"base_score":3.8066624897703196,"endowment":3.8066624897703196,"self_citation_contribution":0.5709993734655481,"citation_network_contribution":0.3128480982933762,"self_endowment_contribution":0.5709993734655481,"citer_contribution":0.3128480982933762,"corpus_percentile":null,"corpus_rank":null,"citation_count":44,"citer_count":44,"citers_with_citation_signal":11,"citers_with_endowment":11,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9513,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT05870319"]},"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1361962,"name":"Lin Wu","orcid":"0000-0003-3166-0530","position":1,"is_corresponding":false},{"id":1158738,"name":"Xiangjiao Meng","orcid":"0000-0001-7380-5510","position":2,"is_corresponding":false},{"id":550882,"name":"Yu Yao","orcid":"0000-0001-9286-4014","position":3,"is_corresponding":false},{"id":1362973,"name":"Wei Zuo","orcid":"0000-0002-4460-0337","position":4,"is_corresponding":false},{"id":1361963,"name":"Wenxiu Yao","orcid":"0009-0008-0812-5656","position":5,"is_corresponding":false},{"id":1361964,"name":"Yanyan Xie","orcid":"0009-0004-6957-8131","position":6,"is_corresponding":false},{"id":1361965,"name":"Yu Zhang","orcid":"0000-0003-2274-429X","position":7,"is_corresponding":false},{"id":1361966,"name":"Jiuwei Cui","orcid":"0000-0001-6496-7550","position":8,"is_corresponding":false},{"id":1250055,"name":"Yongchang Zhang","orcid":"0000-0002-6829-7176","position":9,"is_corresponding":false},{"id":1361967,"name":"Xingya Li","orcid":"0009-0005-0711-5702","position":10,"is_corresponding":false},{"id":1362974,"name":"Wu Zhuang","orcid":null,"position":11,"is_corresponding":false},{"id":1361968,"name":"Jian Fang","orcid":"0000-0003-3697-4563","position":12,"is_corresponding":false},{"id":1361969,"name":"Qiming Wang","orcid":"0000-0002-7813-2885","position":13,"is_corresponding":false},{"id":747099,"name":"Wei Jiang","orcid":"0000-0002-8315-339X","position":14,"is_corresponding":false},{"id":1361970,"name":"Kai Li","orcid":"0000-0002-6895-0024","position":15,"is_corresponding":false},{"id":1361971,"name":"Yuju Bai","orcid":"0000-0003-2897-9997","position":16,"is_corresponding":false},{"id":1361972,"name":"Yongzhong Luo","orcid":"0000-0003-0770-0854","position":17,"is_corresponding":false},{"id":1361973,"name":"Fang Ma","orcid":"0000-0002-0784-6346","position":18,"is_corresponding":false},{"id":1361974,"name":"Yan Yu","orcid":"0000-0001-5598-763X","position":19,"is_corresponding":false},{"id":1199755,"name":"Wei Zheng","orcid":"0000-0001-6107-7261","position":20,"is_corresponding":false},{"id":1361975,"name":"Zhentian Liu","orcid":"0000-0003-4095-8670","position":21,"is_corresponding":false},{"id":649438,"name":"Bin Yang","orcid":"0000-0002-6218-2773","position":22,"is_corresponding":false},{"id":1361976,"name":"Rui Ma","orcid":"0000-0001-9317-9377","position":23,"is_corresponding":false},{"id":1361977,"name":"Yong Fang","orcid":"0000-0001-8310-5673","position":24,"is_corresponding":false},{"id":1361978,"name":"Runxiang Yang","orcid":"0000-0003-3684-5892","position":25,"is_corresponding":false},{"id":1362975,"name":"Liyan Jiang","orcid":null,"position":26,"is_corresponding":false},{"id":1361979,"name":"Jie Hu","orcid":"0009-0006-5445-3736","position":27,"is_corresponding":false},{"id":1361980,"name":"Jiacheng Yang","orcid":"0000-0002-8475-2546","position":28,"is_corresponding":false},{"id":1362976,"name":"Yina Diao","orcid":null,"position":29,"is_corresponding":false},{"id":1361981,"name":"Xiaoping Jin","orcid":"0000-0003-3593-5853","position":30,"is_corresponding":false},{"id":1362977,"name":"Junyou Ge","orcid":null,"position":31,"is_corresponding":false},{"id":1362978,"name":"Yun-Peng Yang","orcid":null,"position":32,"is_corresponding":false},{"id":1361982,"name":"Li Zhang","orcid":"0009-0001-3828-8113","position":33,"is_corresponding":false},{"id":1194085,"name":"Wenfeng Fang","orcid":"0000-0002-6440-8246","position":0,"is_corresponding":true}],"reference_count":27,"raw_metadata":null,"created_at":"2026-07-19T02:47:00.188082Z","pmid":"41124220","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}